← Back to Divi's Laboratories Ltd. overview
Divi's Laboratories Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹9,325 cr | ₹2,191 cr | ₹82.53 | ₹16,932 cr | ₹14,969 cr | 14.64% | 19.49% | 0x | 23.5% |
| FY2024 | ₹7,796 cr | ₹1,600 cr | ₹60.27 | ₹15,470 cr | ₹13,571 cr | 11.79% | 15.96% | 0x | 20.52% |
| FY2023 | ₹7,665 cr | ₹1,824 cr | ₹68.69 | ₹14,439 cr | ₹12,767 cr | 14.29% | 18.55% | 0x | 23.8% |
| FY2022 | ₹8,799 cr | ₹2,960 cr | ₹111.52 | ₹13,375 cr | ₹11,728 cr | 25.24% | 31.4% | 0x | 33.64% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.